Results 51 to 60 of about 724,283 (165)

Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

GastroHep, 2023
Background and Aims. Regulatory pathways compare biosimilars with originator molecules only and not with other biosimilars. With the development of multiple infliximab biosimilars, patients may be asked to transition between them.
Clare Harris, Richard James Harris, David Young, Martin McDonnell, Bridget Clancy, Justin Harvey, Carlos Araujo, Ines Iria, Joao Goncalves, Susan Latter, J. R. Fraser Cummings   +10 more
doaj   +1 more source

Evaluation of novel cardiovascular risk calculators in patients with rheumatoid arthritis

Journal of Rheumatic Diseases
Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Dionicio Angel Galarza-Delgado, Valeria Gonzalez-Gonzalez, Natalia Guajardo-Jauregui, Jesus Alberto Cardenas-de la Garza, Rosa Icela Arvizu-Rivera, Maria Fernanda Elizondo-Benitez, Andrea Lizbeth Guajardo-Aldaco, Jose Ramon Azpiri-Lopez, Iris Jazmin Colunga-Pedraza   +8 more
doaj   +1 more source

Genotype–Phenotype Correlations of Monoallelic PFIC Variants in Pediatric Liver Disease: A Multicenter Retrospective Cohort Study

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Progressive familial intrahepatic cholestasis (PFIC) is classically caused by biallelic pathogenic variants, yet monoallelic variants of uncertain significance (VUS) in PFIC‐associated genes are increasingly identified in children with cholestasis, creating diagnostic uncertainty.
Brett J. Hoskins, Tiziano Pramparo, Chaowapong Jarasvaraparn, Michael J. Wilsey, Voytek Slowik, Lakshmi Kunam, Janis M. Stoll, Ruben E. Quiros‐Tejeira, Simon Lam, Wikrom Karnsakul   +9 more
wiley   +1 more source

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis [PDF]

Journal of Crohn's and Colitis, 2016
CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC].UC patients,
Farkas, Klaudia, Rutka, Mariann, Golovics, Petra A., Végh, Zsuzsanna, Lovász, Barbara D., Nyári, Tibor, Gecse, Krisztina B., Kolar, Martin, Bortlik, Martin, Duricova, Dana, Machkova, Nadezda, Hruba, Veronika, Lukas, Martin, Mitrova, Katarina, Malickova, Karin, Bálint, Anita, Nagy, Ferenc, Bor, Renáta, Milassin, Ágnes, Szepes, Zoltán, Palatka, Károly, Lakatos, Péter L., Lukas, Milan, Molnár, Tamás   +23 more
openaire   +4 more sources

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

Therapeutic Advances in Gastroenterology, 2019
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce.
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches Arenas, Federico Argüelles-Arias   +9 more
doaj   +1 more source

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.

PLoS ONE, 2018
IntroductionTNF-α-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases (IBD), but they are expensive and become ineffective when patients develop anti-IFX or anti-ADA ...
D J Buurman, T Blokzijl, E A M Festen, B T Pham, K N Faber, E Brouwer, G Dijkstra   +6 more
doaj   +1 more source

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. [PDF]

Aliment Pharmacol Ther, 2019
SummaryBackgroundCT‐P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis.AimTo compare the effectiveness and safety of CT‐P13 and the reference product in infliximab‐naive patients with ...
Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A.   +5 more
europepmc   +4 more sources

Biosimilar Infliximab (CT-P13 Remsima™) Is Effective in The Healing of Fistulizing Crohn’s Disease [PDF]

Journal of Surgery, 2017
n ...
Romano, Marco, Ferrante, Emanuele, Romano, Lorenzo, Sgambato, Dolores, Miranda, Agnese, Maurea, Simone, de Sio, Ilario, Mollica, Carmine, Romeo, Valeria, De Musis, Cristiana   +9 more
openaire   +1 more source

A novel three-colour fluorescence in situ hybridization approach for the detection of t(7;12)(q36;p13) in acute myeloid leukaemia reveals new cryptic three way translocation t(7;12;16) [PDF]

, 2013
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).The t(7;12)(q36;p13 ...
Vetter, M, Sabrina Tosi, Plekhanova, O, Fleischman, E, Grigory Tsaur, Tsaur, G, Harbott, J, Sokova, O, Jochen Harbott, Tosi, S, Elena Fleischman, Olga Sokova, Naiel, A, Michael Vetter, Olga Plekhanova, Abdulbasit Naiel   +15 more
core   +1 more source

Synergistic Advanced Oxidation and Physicochemical Treatment Strategies for Antibiotic Removal and Resistance Mitigation in Water

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT The presence of antibiotics in water not only causes environmental pollution but also increases the growth of antibiotic‐resistant bacterial genes, which pose serious threats to human beings and other water residents. Large numbers of people are reportedly affected by the resistant bacterial genes, as many broad‐spectrum antibiotics are not ...
Amir Zada, Shohreh Azizi
wiley   +1 more source